^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    PredicineWES+™

    Company:
    Predicine
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    Predicine’s comprehensive liquid biopsy sequencing solution offers rapid turnaround time for critical clinical applications. From a single sample, we provide low-pass whole genome sequencing (LP-WGS) data combined with broader coverage using WES and/or in-depth profiling using PredicineCARE or PredicineATLAS focused pan cancer panels, based on tumor fraction from the sample.
    Cancer:
    Leukemia, Lymphoma, Solid Tumor
    Gene:
    MSI (Microsatellite instability), TMB (Tumor Mutational Burden)
    Method:
    Liquid biopsy
    Confirmatory trial(s)
    GO42144
    ,
    NCT04449874
    |
    N Engl J Med